Avicanna Inc - Asset Resilience Ratio
Avicanna Inc (AVCN) has an Asset Resilience Ratio of 0.00% as of December 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check AVCN strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2021)
This chart shows how Avicanna Inc's Asset Resilience Ratio has changed over time. See Avicanna Inc net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Avicanna Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Avicanna Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Avicanna Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Avicanna Inc Industry Peers by Asset Resilience Ratio
Compare Avicanna Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Avicanna Inc (2017–2021)
The table below shows the annual Asset Resilience Ratio data for Avicanna Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$22.30 Million ≈ $16.13 Million |
-- |
| 2020-12-31 | 4.15% | CA$1.25 Million ≈ $904.23K |
CA$30.16 Million ≈ $21.81 Million |
-- |
| 2019-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$45.16 Million ≈ $32.67 Million |
-- |
| 2018-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$28.18 Million ≈ $20.39 Million |
-- |
| 2017-12-31 | 0.47% | CA$10.00K ≈ $7.23K |
CA$2.12 Million ≈ $1.53 Million |
-- |
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios … Read more